Lihan Zhou
周砺寒
Lihan Zhou (周砺寒) is the co-founder and CEO of Mirxes (觅瑞), a company developing cancer early-screening kits built on microRNA (miRNA) detection technology . Gaorong's reporting shows him leading the company through multiple raises — an $87M Series C in 2021 and a $50M Series D in 2023 — with a stated focus on blood-based multi-cancer early detection and commercialization across Asia-Pacific markets . In a 2024 talk at Gaorong's healthcare Demo Day, he presented Mirxes' trajectory from miRNA research to a global technology platform and commercial rollout . Beyond his role and quotes at these financing milestones, elsewhere's corpus carries little else on his personal background.
AI-generated — may contain errors, please verify.
Coverage
Congratulations to Mirxes on its successful listing on the Hong Kong Stock Exchange's Main Board — Gaorong Ventures was its earliest institutional investor.
A leading provider of molecular cancer screening products and services.
From Nobel Discovery to Clinical Application: Mirxes Is Transforming Cancer Early Screening with miRNA Technology | Gaorong Ventures
Focused on miRNA technology development, pioneering early cancer screening worldwide.
Mirxes Completes $50 Million Series D to Accelerate Cancer Early-Screening Pipeline R&D and Commercialization
Focused on innovative blood-based early screening products and services for cancer.
"Tiny but Mighty" miRNA: How Cancer Can Be Caught at Its Earliest Stage | Gaorong Ventures "Future"
By applying microRNA to early cancer screening, we can transform cancer from a terminal illness into a chronic disease that can be intercepted at an early stage.
Mirxes Completes $87 Million Series C Round to Develop Early Cancer Screening Products Based on Leading miRNA Technology
Focused on microRNA technology, dedicated to early disease diagnosis.
